THE UNITED STATES PHARMACOPEIAL CONVENTION

Lobbying for THE UNITED STATES PHARMACOPEIAL CONVENTION

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$120,000.00

What this organization spent lobbying with its own staff. Reported using B: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 4

Centers For Medicare and Medicaid Services (CMS)
HOUSE OF REPRESENTATIVES
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 8

S 1784
MAPS Act
HR 4191
MAPS Act
S 3788
CLEAR LABELS Act
HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 4779
National Security, Department of State, and Related Programs Appropriations Act, 2026
S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 8800
National Defense Authorization Act for Fiscal Year 2027

Lobbying activity 3

Health Issues

S. 1784, H.R. 4191 - Mapping America's Pharmaceutical Supply (MAPS) Act - Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling. Issues related to strengthening the resiliency of the U.S. medical supply chain.

Budget/Appropriations

H.R. 5304, S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience. H.R. 4779 - National Security, Department of State, and Related Programs Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.

Defense

S. 2296 - National Defense Authorization Act for Fiscal Year 2026; H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027: Provisions related to supply chain resilience.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.